Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.
Also called NCT01066039
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 202 participants
- Registry
-
NCT01066039
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01066039. Allocation not applicable; no masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2014-07-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control
- Acronym
- GIANT
- Condition
- Hypertension
- Condition
- Diabetes Mellitus, Type II
- Intervention (Drug)
- Bisoprolol
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Collaborator
- Merck Ltd.
Record details
- Record id
cardio:ct-nct01066039- Content hash
f67cb28cb2a2138238a061f13e5a84bbac89d711ef8467f9c47404e956aa0c0b